
    										Summary
    									 
    										Charts
    									 
    									News
    								 
    										Results
    									 
    										Returns
    									 
    										Compare
    									 
    										Share Holding
    									 AllNewsAnnouncementRecos BSE LIVE  Change:  Volume:  Open:  Prv. Close:  Today: 52-Wk: Bid: () Offer: () NSE LIVE  Change:  Volume:  Open:  Prv. Close:  Today: 52-Wk: Bid: () Offer: () Kindly find enclosed Kindly find enclosed Kindly find enclosed Kindly find enclosed Kindly find enclosed Kindly find enclosed Record date for payment of final dividend Kindly find enclosed Kindly find enclosed Kindly find enclosed Kindly find enclosed the outcome of Board meeting. The Company''s UK Subsidiary has received market authorization the details of which are attached Kindly find attached newspaper publication Kindly find enclosed schedule of conference call as attached MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 ,inter alia, to consider and approve the unaudited financial results (Standalone and Consolidated) for quarter ended June 30, 2024 Kindly find enclosed certificate pursuant to regulation 74(5) of SEBI (DP) regulations, 2018 for the quarter ended June 30, 2024 Based on the recommendation of NRC, the Board of Directors has approved the re-appointment of Mr. Abhinna Sundar Mohanty as a Non-Executive Independent Director for a second term of 5 years with effect from July 11, 2024 subject to shareholders approval. Press release intimating receipt of marketing authorization from UKMHRA. Details of issuance of duplicate share certificate issued by the Company as attached Trading window for the designated persons of Marksans Pharma Limited will remain closed from 1st July, 2024 until 48 hours after announcement of Unaudited Financial Results for the quarter ended 30th June, 2024. Kindly find attached transcript of earnings call Q4FY24 Kindly find attached Newspaper publication of Audited financial results for quarter and year ended March 31, 2024 Kindly find enclosed Kindly find enclosed The Board has approved final dividend of Rs. 0.60 per equity share Investor Presentation on financial results for FY24 Kindly find enclosed the results for FY24 Kindly find enclosed the outcome of Board meeting As enclosed Kindly find enclosed the secretarial compliance report for the year ended March 31, 2024 Details of investors call as attached MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 ,inter alia, to consider and approve Audited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and year ended March 31, 2024 and;Recommendation of dividend for FY2023-24 This is to inform that a routine eGMP inspection was conducted by USFDA at manufacturing facility of the Company in Verna Goa. There was no data integrity observation. Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.   Sr. No. Particulars Details   1 Name of Company MARKSANS PHARMA LTD.   2 CIN NO. L24110MH1992PLC066364   3 Report filed for FY 2023-2024  Details of the Current block (all figures in Rs crore):  4 2 - year block period (Specify financial years)*  2023-24,02024-25, 2025-26    5 Incremental borrowing done in FY (T)(a)  0.00   6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00   7 Actual borrowing done through debt securities in FY (T)(c) 0.00   8  Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0   8Quantum of (d), which has been met from (c)(e)* 0  9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0   Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2023-24. 2024-25, 2025-26 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00    Name of the Company Secretary :-Harshavardhan PanigrahiDesignation :-Company Secretary Name of the Chief Financial Officer :- Jitendra Sharma Designation : -Chief Financial Officer  Date: 15/04/2024 Format of Initial Disclosure to be made by an entity identified as a Large Corporate.  Sr. No. Particulars Details  1Name of CompanyMARKSANS PHARMA LTD. 2CIN NO.L24110MH1992PLC066364 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY A+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE     We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No   Name of the Company Secretary: Harshavardhan Panigrahi   Designation: Company Secretary  EmailId: harshavardhan@marksanspharma.com  Name of the Chief Financial Officer: JItendra Sharma  Designation: Chief Financial Officer  EmailId: jitendra@marksanspharma.com    Date: 15/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.  Kindly find enclosed herewith under regulation 74(5) of DP regulations for quarter ended March 31, 2024 received form big share Services Private Limited Pursuant to regulation 40(9) & 40(10) of SEBI LODR, kindly find enclosed compliance certificate issued by Sanjay Dholakia & Associates-PCS, for FY2024 We confirm that all activities in relation to share transfer facilities of the Company during the FY2024 were maintained by RTA - Big share services private limited We have received intimation from our RTA regarding issuance of duplicate share certificate the details of which have been attached Quick Links Trending Now Hot on Web In Case you missed it Top Calculators Top Searched Companies Popular Companies Popular Companies Top Commodities Top Story Listing Top Prime Articles Top Slideshow Private Companies Top Videos Latest News Follow us on: